A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder

[1]  N. Iwata,et al.  Efficacy and Safety of Desvenlafaxine 25 and 50 Mg/Day in a Randomized, Placebo-Controlled Study of Depressed Outpatients , 2013, Journal of psychiatric practice.

[2]  D. Sheehan,et al.  Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale , 2011, International clinical psychopharmacology.

[3]  A. Gelenberg.  The prevalence and impact of depression. , 2010, The Journal of clinical psychiatry.

[4]  J. Guelfi,et al.  Desvenlafaxine for the Prevention of Relapse in Major Depressive Disorder: Results of a Randomized Trial , 2010, Journal of clinical psychopharmacology.

[5]  R. DeRubeis,et al.  Antidepressant drug effects and depression severity: a patient-level meta-analysis. , 2010, JAMA.

[6]  K. Demyttenaere,et al.  Patient-assessed versus physician-assessed disease severity and outcome in patients with nonspecific pain associated with major depressive disorder. , 2009, Primary care companion to the Journal of clinical psychiatry.

[7]  S. K. Padmanabhan,et al.  A Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible-Dose Desvenlafaxine Treatment in Outpatients with Major Depressive Disorder , 2009, CNS Spectrums.

[8]  S. Montgomery,et al.  Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial , 2008, International clinical psychopharmacology.

[9]  M. Liebowitz,et al.  A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. , 2007, The Journal of clinical psychiatry.

[10]  B. Pitrosky,et al.  A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder , 2007, International clinical psychopharmacology.

[11]  N. DeMartinis,et al.  A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. , 2007, The Journal of clinical psychiatry.

[12]  P. Bech.  Rating scales in depression: limitations and pitfalls , 2006, Dialogues in clinical neuroscience.

[13]  Olga V. Demler,et al.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. , 2005, Archives of general psychiatry.

[14]  M. Detke,et al.  Placebo Response and Antidepressant Clinical Trial Outcome , 2003, The Journal of nervous and mental disease.

[15]  H. Möller,et al.  Rating depressed patients: observer- vs self-assessment. , 2000, European psychiatry : the journal of the Association of European Psychiatrists.

[16]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[17]  S. K. Padmanabhan,et al.  Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. , 2009, Clinical therapeutics.

[18]  M. Liebowitz,et al.  Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. , 2008, Current medical research and opinion.

[19]  R. Hu.  Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) , 2003 .